New Second-Line Option for Advanced Gastric Cancer

The results of a phase III randomized trial found that the anti-angiogenesis antibody ramucirumab improved survival in advanced, previously treated gastric cancer.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news